spacer
home > epc > spring 2017 > getting interactive
PUBLICATIONS
European Pharmaceutical Contractor

Getting Interactive

The pharmaceutical market is booming, evidenced by revenue numbers which exceeded the $1 trillion milestone in 2015, as noted in the International Trade Commission’s 2016 Top Markets Report on Pharmaceuticals (1). A good portion of that is invested in research, so there are a lot of promising developments happening in the clinical trial space. Despite these advancements, however, many industry investments in research are wasted due to problems with clinical supply management.

To get to the heart of the issue, 200 studies that wrapped up over the past two years have recently been reviewed. Out of them, 62% of the material packaged and released was not even used – two thirds of supplies never actually made it to a patient, meaning there was unnecessary spending.

Assessing the Costs

What makes up the costs associated with clinical supplies? One of the biggest considerations is drug expenses, which includes everything from production to packaging and storage. For these factors, there are fixed and variable costs that must be closely examined – for example, if a trial has 1,000 patients getting three kits each, 3,000 kits must be produced. It is also important to create an overage as it is impossible to know where those patients are going to be at all times. Buffers are also necessary and it is vital to ensure that sites do not run out of drugs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stefan Dürr has been working with interactive response technologies for 12 years and is currently Senior Director of Project Management at Cenduit. He is responsible for global project management and support services groups at the company with teams in India, Japan, Switzerland and the US. Stefan holds a Master’s of Science in Molecular Biology and is passionate about finding innovative solutions for clinical supply challenges.
spacer
Stefan Dürr
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection

Boston, MA and Washington D.C. – August 15, 2017 -- Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In the same way that the fully automated HD-1 Analyzer offers detection and measurement of biomarkers with unprecedented sensitivity, the SR-Plex will use single molecule measurements to assess previously undetectable proteins and can significantly reduce sample volume requirements when compared to alternative approaches, all in a benchtop format that can be easily integrated with existing automation platforms. The first unveiling of the SR-Plex will happen today at the Next Generation Dx Summit in Washington, D.C.
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

ManuPharma 2017

6-7 December 2017, Steigenberger Frankfurter Hof, Frankfurt

Europe's first peer-led pharma event for Heads of Tech Ops, Heads of Manufacturing Ops and Site Leads.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement